Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.28 +0.06 (+0.45%)
Official Closing Price Updated: 7:00 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 594,402
Open 13.27
Bid (Size) 13.11 (1)
Ask (Size) 13.47 (1)
Prev. Close 13.22
Today's Range 13.26 - 13.33
52wk Range 12.77 - 16.39
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
In the headline deal, Takeda acquires global rights from AC Immune of Switzerland for $100 million upfront and up to $2.1B in milestones. 
Via Talk Markets
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas. 
Via Benzinga

Performance

YTD
-7.39%
-7.39%
1 Month
-0.60%
-0.60%
3 Month
-10.39%
-10.39%
6 Month
-5.21%
-5.21%
1 Year
-17.77%
-17.77%

More News

Read More
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
Via Benzinga
Why Is AC Immune (ACIU) Stock Up 45% Today?
Via InvestorPlace
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
Catalyst's New CEO Has Big Ideas For The Small Biotech
Via Investor's Business Daily
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
Via Benzinga
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023
Via InvestorPlace
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Via Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
Via Investor's Business Daily
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
From Takeda Pharmaceutical Company Limited
Via Business Wire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
From Centogene NV
Via GlobeNewswire
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Hot List: 3 AI Stocks Worth Buying on Weakness
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
From Takeda Pharmaceutical Company Limited
Via Business Wire
FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus
Via Benzinga
Exposures Product Safety
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.